Concepedia

Burçin Şimşek

BŞ

Statistics

Publications

28

Citations

3.6K

H-Index

19

Active since

2016

Affiliations

Bristol-Myers Squibb (United States)(Current)

Memorial Sloan Kettering Cancer Center

Institut Gustave Roussy

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Burçin Şimşek is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and cancer immunotherapy.

Publications per year

2016–2024

28

Publications

28

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Padmanee Sharma, Russell K. Pachynski, Vivek Narayan et al. · Cancer Cell · 2020 · 393 citations · Full text

Medicine, Oncology, Pharmacology +15

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto et al. · The Lancet Oncology · 2022 · 307 citations · Full text

Medicine, Oncology, Pharmacology +10

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Robert J. Motzer, Paul Russo, Viktor Grünwald et al. · The Lancet · 2023 · 172 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · Annals of Oncology · 2020 · 116 citations · Full text

Medicine, Oncology, Pharmacology +11

1–5 of 28